ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GRFS Grifols SA

7.685
0.215 (2.88%)
Last Updated: 20:59:19
Delayed by 15 minutes
Name Symbol Market Type
Grifols SA NASDAQ:GRFS NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.215 2.88% 7.685 7.68 7.69 7.73 7.5101 7.58 1,519,948 20:59:19

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

29/12/2023 2:46pm

Edgar (US Regulatory)


 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December  2023

 

Commission File No. 001-35193

 

Grifols, S.A. 

(Translation of registrant’s name into English)

 

Avinguda de la Generalitat, 152-158 

Parc de Negocis Can Sant Joan 

Sant Cugat del Valles 08174 

Barcelona, Spain 

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F xForm 40-F ¨

 

 

 

 

 

 

Grifols, S.A.

 

TABLE OF CONTENTS

 

Item   Sequential Page Number
       
1. Other Inside Information, dated December 29, 2023 d 3

 

 

 

 

  Grifols, S.A.

Avinguda de la Generalitat 152-158
08174 Sant Cugat del Vallès
Barcelona - ESPAÑA

Tel. [34] 935 710 500
Fax [34] 935 710 267

www.grifols.com

 

Pursuant to the provisions of article 226 of the Law 6/2023, of March 17, on Securities Markets and Investment Services, Grifols S.A. ("Grifols" or the "Company") hereby informs about the following

 

INSIDE INFORMATION

 

Following the Inside Information communication published today regarding the partial sale of Grifols' stake in Shanghai RAAS Blood Products Co., Ltd. ("SRAAS"), Grifols informs that the capital gain resulting from this transaction, compared to the acquisition price of SRAAS shares, amounts to approximately 250 million euros.

 

In Barcelona, on 29 December 2023

 

   
Nuria Martín Barnés  
Secretary to the Board of Directors  

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

  Grifols, S.A.
   
     
  By: /s/ David I. Bell
    Name: David I. Bell
    Title: Authorized Signatory

 

Date:  December 29, 2023

 

 

 


1 Year Grifols Chart

1 Year Grifols Chart

1 Month Grifols Chart

1 Month Grifols Chart